The current PE ratio of ANIP can't be determined, as the TTM EPS of -$0.55 is negative. The most recent PE ratio recorded for Ani Pharmaceuticals was 53.97 in June 2024.
Over the last ten years, the average PE ratio of Ani Pharmaceuticals has been 452.72. Over the past ten years, ANIP's PE ratio was at its highest in the Jun 2018 quarter at 6,680, with a price of $66.8 and an EPS of $0.01. The Sep 2015 quarter recorded the bottom point at 13.21, with a price of $39.51 and an EPS of $2.99.
Maximum annual increase: 429.36% in 2016
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
2023 | 64.12 | N/A | $55.14 | $0.86 |
2022 | N/A | N/A | $40.23 | -$3.05 |
2021 | N/A | N/A | $46.08 | -$3.4 |
2020 | N/A | N/A | $29.04 | -$1.88 |
2019 | 120.92 | 251.82% | $61.67 | $0.51 |
2018 | 34.37 | N/A | $45.02 | $1.31 |
2017 | N/A | N/A | $64.45 | -$0.09 |
2016 | 178.29 | 429.36% | $60.62 | $0.34 |
2015 | 33.68 | 55.85% | $45.13 | $1.34 |
2014 | 21.61 | N/A | $56.39 | $2.61 |
2013 | N/A | N/A | $20.08 | -$0.92 |
2012 | N/A | N/A | $7.38 | -$7.62 |
2011 | N/A | N/A | $18.08 | -$18.9 |
2010 | N/A | N/A | $59.04 | -$25.26 |
2009 | N/A | N/A | $52.2 | -$50.4 |
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
Sep 2024 | N/A | N/A | $59.66 | -$0.55 |
Jun 2024 | 53.97 | 26.48% | $63.68 | $1.18 |
Mar 2024 | 42.67 | -33.45% | $69.13 | $1.62 |
Dec 2023 | 64.12 | -41.47% | $55.14 | $0.86 |
Sep 2023 | 109.55 | N/A | $58.06 | $0.53 |
Jun 2023 | N/A | N/A | $53.83 | -$0.48 |
Mar 2023 | N/A | N/A | $39.72 | -$1.72 |
Dec 2022 | N/A | N/A | $40.23 | -$3.05 |
Sep 2022 | N/A | N/A | $32.14 | -$4.63 |
Jun 2022 | N/A | N/A | $29.67 | -$4.45 |
Mar 2022 | N/A | N/A | $28.11 | -$4.68 |
Dec 2021 | N/A | N/A | $46.08 | -$3.4 |
Sep 2021 | N/A | N/A | $32.82 | -$1.83 |
Jun 2021 | N/A | N/A | $35.05 | -$1.42 |
Mar 2021 | N/A | N/A | $36.14 | -$1.28 |
Stock name | PE ratio | Market cap |
---|---|---|
RPRX Royalty Pharma plc | 17.41 | $19.27B |
JAZZ Jazz Pharmaceuticals plc | 18.26 | $8.22B |
NVS Novartis AG | 18.47 | $215.98B |
CAH Cardinal Health Inc | 23.57 | $30.69B |
PFE Pfizer Inc | 34.61 | $149.04B |
TEVA Teva Pharmaceutical Industries Ltd | N/A | $18.98B |
CLDX Celldex Therapeutics Inc | N/A | $1.49B |
ANIP Ani Pharmaceuticals Inc | N/A | $1.22B |
The current price to earnings ratio of ANIP can't be calculated, as its EPS of -$0.55 is negative.
Over the last ten years, the quarterly PE ratio reached a historic high of 6,680 in the Jun 2018 quarter.
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from and Sharadar.